DUNHAM TRUST Co’s Design Therapeutics DSGN Stock Holding History
Bought
Maintained
Sold
Other funds holding DSGN
BBA
DUNHAM TRUST Co's DSGN Position: Q3 2026 in Review
DUNHAM TRUST Co held its Design Therapeutics (DSGN) position steady in Q3 2026 at 7,668,710 shares worth $96.4M. The position accounts for 43.6% of the portfolio, ranked #1.
DUNHAM TRUST Co first reported a position in DSGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $111M in Q2 2026. 140 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.
- DUNHAM TRUST Co held 7,668,710 shares of Design Therapeutics worth $96.4M as of Q3 2026.
- DUNHAM TRUST Co left its Design Therapeutics share count unchanged in Q3 2026.
- Design Therapeutics made up 43.6% of DUNHAM TRUST Co's portfolio in Q3 2026, its #1 holding.
- DUNHAM TRUST Co first reported a position in Design Therapeutics in Q4 2025 and has held it in 3 quarters since.
- DUNHAM TRUST Co's Design Therapeutics position peaked at $111M in Q2 2026.
- 140 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.
Based on DUNHAM TRUST Co's 13F filing for Q3 2026, filed 16 Nov 2026.